In 2016, the USC Norris Comprehensive Cancer Center developed a novel combination vaccine, PDL1-Vax, which integrates PD-1/PD-L1 immune checkpoint blockade with tumor-specific antigen recognition (51). This evidence concerns the gene CD274 and neoplasm.